These results underlined significant preclinical activity of this inhibitor in MYC-driven B-NHL, including the aggressive, so-called “double hit” lymphoma (DHL), characterized by simultaneous oncogenic activation of MYC and/or BCL2/BCL6 (Johnson-Farley et al., 2015). The gene discussed is MYC; the disease is lymphoma.